Castle Biosciences signals $385M-$395M 2026 revenue outlook as TissueCypher targets 50%-52% volume growth

• "Our team closed out a very successful third quarter, reflecting our focused execution and disciplined expense management" (Founder, CEO, President & Director Derek Maetzold), and "we delivered revenue of $102.9 million, 24% growth compared to the third quarter of 2025" while "TissueCypher test

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.